Incorporation of radiotherapy fractionation in the combined-modality treatment of limited small-cell lung cancer.
Publication/Presentation Date
4-1-1993
Abstract
Although systemic failure continues to plague patients receiving combined-modality treatment for limited small-cell lung cancer (SCLC), improvements in chemotherapy, including use of cisplatin/etoposide-based regimens, and radiotherapy have produced increases in median, 2-year, and 5-year survival over the last decade. Employing more conservative volumes of radiotherapy in more aggressive ways, today about 50% of SCLC patients will survive 2 years and 30%, 5 years. Moreover, integrating radiotherapy with chemotherapy early in the course of treatment can potentially eliminate resistant clones. The various factors in radiotherapy, including dose, volume, fractionation, and timing, therefore deserve scrutiny in the reporting and design of clinical trials.
Volume
103
Issue
4 Suppl
First Page
418
Last Page
418
ISSN
0012-3692
Published In/Presented At
Turrisi A. T., 3rd (1993). Incorporation of radiotherapy fractionation in the combined-modality treatment of limited small-cell lung cancer. Chest, 103(4 Suppl), 418S–422S. https://doi.org/10.1378/chest.103.4_supplement.418s
Disciplines
Medicine and Health Sciences
PubMedID
8384972
Department(s)
Department of Medicine
Document Type
Article